We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Eisai Company Ltd (PK) | USOTC:ESALY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 61.51 | 61.51 | 61.86 | 0.00 | 01:00:00 |
From Jun 2021 to Jun 2024
By Kosaku Narioka
Eisai Co. shares fell as much as 9.2% early Thursday morning after a Japanese government panel sought additional data for a review of the company's Aduhelm drug for Alzheimer's.
Biogen Inc. and Eisai, which co-developed the medication, said they remained committed to bringing Aduhelm to patients in Japan soon.
Aduhelm's commercial potential has dropped significantly given recent regulatory developments in Europe and Japan, as well as criticism over its regulatory approval in the U.S., Nomura analyst Motoya Kohtani said in a report.
Earlier this month, the European Medicines Agency recommended not granting Aduhelm marketing authorization.
Biogen and Eisai said they will continue to engage with Japanese government officials on additional data requirements.
Eisai shares were 8.8% lower at 6,498 yen ($56.94) at the close of the morning session in Tokyo.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
December 22, 2021 22:12 ET (03:12 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Eisai (PK) Chart |
1 Month Eisai (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
